Roche reports positive lung cancer trial data for Tecentriq

Roche has announced new clinical trial data that demonstrates the benefits of Tecentriq, its new lung cancer therapy.

Results presented at the European Society of Medical Oncology's 2016 annual meeting have shown that the drug can deliver significant survival benefits for non-small cell lung cancer patients whose disease has progressed on or after treatment with one or more types of platinum-based chemotherapy.

In the phase III OAK trial, the drug was shown to help people live a median of 13.8 months, which was 4.2 months longer than those treated with docetaxel chemotherapy, regardless of their levels of programmed death-ligand 1 (PD-L1) expression.

The findings included overall survival results for squamous and nonsquamous disease types, showing the broad-based benefits Tecentriq can potentially provide.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "Even people whose disease had low or no observed PD-L1 expression still showed a significant benefit from the medicine."

Currently, the drug is being evaluated in eight phase III lung studies, assessing Tecentriq alone or in combination with other treatments in patients with early and advanced stages of lung cancer.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.